At the Sohn San Francisco Conference on October 15, 2024, Xiaoying Tian, founder of Saturn V Capital Management, delivered a compelling pitch on the promising advancements in bladder cancer treatment, spotlighting CG Oncology's innovative approach. As the prevalence of bladder cancer continues to rise, Tian’s insights on the pressing medical need and the future of treatment strategies resonate deeply within the healthcare investment community.
Unmet Needs in Bladder Cancer: A Market Worth $58 Billion
Bladder cancer ranks among the most commonly diagnosed cancers in the United States, with a disheartening recurrence rate that severely impacts patient quality of life. Tian articulated that most bladder cancer cases are diagnosed as non-muscle invasive bladder cancer (NMIBC), a condition that often leads...
